SecBot SecBot
8-K ·Filed Nov 13, 2026

MGNX

MACROGENICS INC
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 9h ago SEC0001125345-26-000077
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor next MGC026 data update expected mid-2027 and enrollment progress in SCCHN monotherapy cohort and lorigerlimab CCGC cohort by YE2026. The company's cash runway through 2028 reduces near-term financing risk.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

MGNX drug pipeline →

lorigerlimab

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 with no registrational trial announced. If the lower-dose LINNET data in H1 2027 is compelling enough to support a registrational path, a potential BLA filing would likely be at least 2-3 years away.
Next catalyst
None dated

What to watchThe next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics posted a corporate presentation on its website with updated clinical data for its B7-H3 ADC MGC026, showing a 27% best overall response rate in heavily pretreated SCCHN patients with no discontinuations due to TRAEs. The company also reported $288M in cash as of September 30, 2026, with cash runway through 2028, and highlighted progress across its pipeline including MGC028, MGC030, and lorigerlimab.

Key Facts

  • MGC026 showed 27% best overall response rate (6/22) and 18.2% confirmed ORR (4/22) in SCCHN expansion cohort at 7.5 mg/kg Q3W
  • 0% TRAEs leading to discontinuation in SCCHN cohort; no ILD, pneumonitis, or ocular toxicity reported
  • $288M cash equivalents and marketable securities as of September 30, 2026
  • Cash runway guidance through 2028
  • Total revenues for 9 months ended Sep 30, 2026: $58M vs $67M in same period 2025
  • R&D expense for 9 months ended Sep 30, 2026: $104M vs $113M in same period 2025
  • Next MGC026 update anticipated mid-2027
  • Lorigerlimab CCGC cohort: 25% cORR (4/16 evaluable) at 6 mg/kg Q3W; plan to enroll 20 additional patients at 3 mg/kg Q3W by YE2026

Financial Impact

Cash position of $288M provides runway through 2028; revenues declining YoY ($58M vs $67M for 9-month period)

cashrevenuer&d expense

Risk Factors

  • Early-stage clinical data (Phase 1) with small sample sizes; data not final and subject to change
  • Revenues declining year-over-year; company has no approved products generating revenue
  • Competitive B7-H3 ADC landscape with multiple programs in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001125345-26-000077
Document: mgnx-20261113.htm0001125345-26-000077
Document: 0001125345-26-000077-index-headers.html0001125345-26-000077
Document: 0001125345-26-000077-index.html0001125345-26-000077
Document: 0001125345-26-000077.txt0001125345-26-000077

Track record

21 reports on MGNX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Viewing Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026